Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premenopause | 1 | 2015 | 40 | 0.460 |
Why?
|
| Adnexal Diseases | 1 | 2015 | 23 | 0.460 |
Why?
|
| Genital Neoplasms, Female | 3 | 2018 | 45 | 0.370 |
Why?
|
| Endometrial Neoplasms | 3 | 2020 | 115 | 0.360 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1692 | 0.250 |
Why?
|
| Lymph Node Excision | 2 | 2016 | 176 | 0.230 |
Why?
|
| Uterine Neoplasms | 2 | 2015 | 112 | 0.210 |
Why?
|
| Ovarian Neoplasms | 3 | 2017 | 467 | 0.200 |
Why?
|
| Referral and Consultation | 2 | 2015 | 572 | 0.170 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2017 | 14 | 0.150 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2017 | 58 | 0.150 |
Why?
|
| Brachytherapy | 1 | 2018 | 93 | 0.140 |
Why?
|
| Salpingo-oophorectomy | 1 | 2017 | 10 | 0.130 |
Why?
|
| Peritoneum | 1 | 2017 | 40 | 0.130 |
Why?
|
| Omentum | 1 | 2017 | 48 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 365 | 0.130 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2015 | 16 | 0.120 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 34 | 0.120 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 97 | 0.120 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2015 | 48 | 0.110 |
Why?
|
| Cyclic S-Oxides | 1 | 2014 | 2 | 0.110 |
Why?
|
| Thiadiazoles | 1 | 2014 | 6 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2014 | 128 | 0.110 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2015 | 63 | 0.110 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 62 | 0.110 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 79 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 164 | 0.100 |
Why?
|
| Gynecology | 1 | 2015 | 129 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2015 | 245 | 0.100 |
Why?
|
| Hysterectomy | 1 | 2014 | 201 | 0.100 |
Why?
|
| SEER Program | 3 | 2020 | 222 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 403 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 318 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 483 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 584 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2015 | 998 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1363 | 0.080 |
Why?
|
| Aged | 8 | 2020 | 21446 | 0.070 |
Why?
|
| Survival Rate | 3 | 2020 | 2204 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2876 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 1013 | 0.060 |
Why?
|
| Female | 10 | 2020 | 71382 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 7137 | 0.060 |
Why?
|
| Medicare | 2 | 2020 | 468 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3863 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2014 | 3169 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 1310 | 0.040 |
Why?
|
| Humans | 10 | 2020 | 133147 | 0.040 |
Why?
|
| Middle Aged | 5 | 2018 | 28911 | 0.040 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2018 | 21 | 0.040 |
Why?
|
| Adult | 5 | 2018 | 31608 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 91 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 5188 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2018 | 17520 | 0.040 |
Why?
|
| United States | 3 | 2020 | 11711 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 50 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 49 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 61 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 82 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 2017 | 78 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 135 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 168 | 0.030 |
Why?
|
| Prognosis | 2 | 2015 | 5030 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1240 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 72 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 398 | 0.030 |
Why?
|
| Transcription Factor HES-1 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 306 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 449 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 741 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 158 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2015 | 395 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1201 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 1097 | 0.020 |
Why?
|
| Heart Rate | 1 | 2014 | 586 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1307 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1463 | 0.020 |
Why?
|
| Young Adult | 2 | 2016 | 9917 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 1013 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1862 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 1411 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1351 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 3794 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1849 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5434 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 3715 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2750 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 6340 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 10930 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 4915 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2015 | 13093 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 18930 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 36189 | 0.010 |
Why?
|